The biopharmaceutical company, Innate Pharma, received a blow when the U.S. Food and Drug Administration (FDA) announced a partial hold on the studies of their leading proprietary program, lacutamab. This decision came after the unfortunate death of a patient.
The partial hold has temporarily paused new patient enrollment in both Phase 2 and Phase 1b studies of lacutamab. The FDA's action was prompted by a fatal case of hemophagocytic lymphohistiocytosis, a rare hematologic disorder.
In response, Innate Pharma is actively working to address the FDA's requests. This includes incorporating risk mitigation and management strategies specifically aimed at preventing hemophagocytic lymphohistiocytosis in future lacutamab studies.
However, it is important to note that patients already receiving treatment and experiencing clinical benefits will be allowed to continue their therapy uninterrupted. Moreover, this setback is not expected to delay the release of Phase 2 study data as all patients have already been recruited.
Despite this setback, Innate Pharma remains resilient and committed to moving forward with their groundbreaking research. As the situation develops, the company will continue to work closely with the FDA to ensure the safety and efficacy of lacutamab.
Innate Pharma's shares have taken a hit due to this news, with premarket trading showing an 11% decline from $2.47 to $2.19.
Alstom Reports Sales Increase in First Half
Toronto Stocks Rally at Midday
Our Latest News
Bonds: A More Attractive Option
Bonds are proving to be attractive to investors in today's uncertain market. This article discusses the benefits of investing in bonds and using options strateg...
Hapag-Lloyd Shares Drop on Lower Freight Rates
Hapag-Lloyd's shares decline after reporting lower earnings and freight rates for Q4.
The Art of Winning on 'Jeopardy!'
Former 'Jeopardy!' champion Ken Jennings shares the importance of timing and mastering the buzzer to win the game show, along with his secret sauce for success.